甲状腺相关性眼病的诊断性生物标志物研究进展  

Research progress in diagnostic biomarkers for thyroid-associated ophthalmopathy

作　　者：张浩 赵婧[1] 葛小宁 董雅儒[1] ZHANG Hao;ZHAO Jing;GE Xiaoning;DONG Yaru(Department of Ophthalmology,the Second Hospital of Jilin University,Changchun 130041,Jilin Province,China)

机构地区：[1]吉林大学第二医院眼科,吉林省长春市130041

出　　处：《眼科新进展》2022年第7期562-567,共6页Recent Advances in Ophthalmology

基　　金：吉林省教育厅科学研究项目(编号:JJKH20201089KJ)。

摘　　要：甲状腺相关性眼病(TAO)是由自身免疫反应引起的慢性致盲性眼部疾病,其与甲状腺功能障碍密切相关。TAO的诊断主要基于眼部临床表现、体征、实验室检查、影像学特征以及甲状腺功能障碍病史。迄今为止,该病尚无特异性标志物,这给TAO的早期诊断带来巨大困难,尤其部分TAO患者在诊断为甲状腺功能障碍前就表现出难以忍受的眼部症状。因此,实现TAO早期诊断并给予相应干预,控制其进一步恶化,将对患者的预后及生活质量有着重要意义。本文将简要讨论TAO的致病因素、发病机制以及诊断局限性,重点对近年来TAO诊断性生物标志物研究进展予以综述。Thyroid-associated ophthalmopathy(TAO)is a chronic blinding disease caused by autoimmune reactions,which is closely related to thyroid dysfunction.The diagnosis of TAO is mainly based on ocular manifestations,signs,laboratory tests,imaging features,as well as a history of thyroid dysfunction.To date,there is no specific marker for this disease,which poses great difficulties in the early diagnosis of TAO,especially for a few TAO patients who have shown unbearable eye symptoms before the diagnosis of thyroid dysfunction.Therefore,early diagnosis of TAO and corresponding intervention are of great significance to prevent its deterioration and improve the prognosis and quality of life of patients.This article briefly discusses the pathogenic factors,pathogenesis,and diagnostic limitations of TAO,with focus on the recent research progress in diagnostic biomarkers for TAO.

关 键 词：甲状腺相关性眼病 生物标志物 血液 尿液 泪液 

分 类 号：R771.3[医药卫生—眼科]